ACR Image Metrix
™ is pleased to announce that the DCE-MRI study, as commissioned by
Bionomics Ltd.
, was submitted as an abstract by Bionomics to the American Society of Clinical Oncology (ASCO) and has been accepted to be presented as a part of the scientific program during the general poster session at the
ASCO Annual Meeting
, which will take place June 4-8, 2010, in Chicago, Illinois, at McCormick Place.
As a drug discovery and development organization focusing on new treatments for cancer and serious disorders of the central nervous system, Bionomics selected ACR Image Metrix to perform the imaging components of this study.
“Their extensive experience in the utilization of novel imaging techniques to serve as biomarkers and history of partnering with regulatory agencies to develop standards for imaging acquisition, data normalization, data extraction and the assessment of variability made the selection of ACR Image Metrix as our imaging CRO appropriate for this project,” stated Bionomics Vice President of Discovery Research, Gabriel Kremmidiotis, Ph.D.
The completion of this Phase I clinical trial, which involved
MRI (DCE-MRI)
quantitative analysis, was a two-stage dose escalation design involving Bionomics’ BNC 105P-001, a novel vascular disrupting agent staged in patients with advanced solid tumors.
“Teaming up with Bionomics to complete this study turned out to be a success and we are pleased with the results. This is a major milestone for ACR Image Metrix in our ability to conduct novel imaging for both pharmaceutical and biotech companies,” stated General Manager of ACR Image Metrix, Michael J. Morales.
ACR Image Metrix will also be exhibiting at the ASCO Annual Meeting, Booth 19097.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.